Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
Clear All
Diagnostics
19 Results

Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.

An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.

The George Mason University Center for Infectious Disease Research Biomedical Research Laboratory (BRL) is one of the NIAID-supported Biocontainment Laboratories. The RBL supports research programs in the Center for Infectious Disease Research focusing on host response using proteomics and nanote

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.

The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories.

The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.

The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u

The Immcantation framework is developed as a start-to-finish analytical ecosystem for large-scale characterization of B cell receptor (BCR) and T cell receptor (TCR) repertoires from high-throughput adaptive immune receptor repertoire sequencing (AIRR-seq) datasets.

The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.

Note: Devices are excluded.

The NIAID Centralized Sequencing Program serves as a genomics resource for NIAID human subjects research studies to help address interrelated challenges in clinical care and NIAID Intramural research. Any NIAID participant is eligible to receive genome sequencing and associated services through this protocol.

This core serves as a national resource for the long-term care and study of animals after irradiation, since 2007. The Radiation Late Effects Program facilitates the conduct of late-stage preclinical studies of mitigators of radiation damage in nonhuman primates.

The primary objective of the response team is to develop and foster overseas relationships through the support of research studies and clinical trials.

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.